How pharma companies are using social media to learn about drugs' affects on patients
In an attempt to gain more health information, United Kingdom-based pharmaceutical company GlaxoSmithKline has begun collecting data from social media sites such as Facebook and Twitter that mention any of a company’s 1,000 different drugs.
In its partnership with United States-based informatics company Epidemico, the two found over six million Twitter mentions and more than 15 million Facebook hits. Epidemico assists GSK in filtering the data, getting rid of irrelevant posts and standardizing the language around complex drug names and medical conditions.
“People really are communicating a lot online on social media,” said Greg Powell, director of pharmacovigilance at GlaxoSmithKline. “There’s actually a wealth of information here that potentially hasn’t been tapped into until recently. The question is ‘If people are talking about our products, should we be listening to what they’re saying?’ The answer is ‘Of course’.”
GSK uses the information similar to the way it uses drug safety and usage data from other sources. In one instance, Facebook posts analyzed through this plan led to a recall of an over-the-counter drug in Australia that had a manufacturing defect.
However, there are times when social media helps reveal information pharmaceutical companies previously never had access to. For example, one company received data showing how people are abusing their drugs, while another has been tracking how well they’re communicating to their patents.
This information can’t be found anywhere else, and also helps companies make its drugs tougher to abuse.
In addition, the social media insights can be very helpful when comparing a drug’s benefits to adverse affects. Numbers show 29 percent of drug mentions the company has tracked on social media acknowledge the benefits patients received, while 16 percent investigate benefits around adverse affects. Meanwhile, 11 percent of postings compared the drug to other options of treatment.
While GSK has used social media data for postmarket research, American pharmaceutical company Merck used the online patient network called PatientsLikeMe to do premarket research on Belsombra, which is a drug used to treat insomnia.
RELATED TOPIC: 4 reasons why social media empowers your medical practice
What Merck discovered after examining data from the 90,000 insomnia patients on PatientsLikeMe was even patients who tell their doctor they’re satisfied with the sleep medication they’re taking often still have trouble sleeping. The benefits of existing drugs usually decline over time and people said the drugs help them get to sleep, but didn’t keep them from waking up in the middle of the night.
The value proposition for Belsomra addressed some of these problems. It was designed to work over the long term for chronic insomnia, and to help people sleep the whole night. Fitzgerald believes this type of data helped Merck to decide how best to market the drug.
Click here to read the latest edition of Healthcare Global magazine!
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”